San Raffaele Telethon Institute for Gene Therapy
Latest From San Raffaele Telethon Institute for Gene Therapy
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.
Cell and gene therapies, described as the most exciting developments in the life sciences industry, pick up more momentum with every passing month. The spiraling enthusiasm for an activity that will change how health care is delivered was captured by GE, GSK and other key industry players at a leading UK life sciences industry meeting in spring 2017.
There are still many lessons to be learned in commercializing cell and gene therapies. Experts in the industry discussed challenges and best practices at the Alliance for Regenerative Medicine's annual meeting in October.
Celgene pays Agios $200m up front for collaboration in immuno-oncology. Biogen inks pacts with Regenxbio and Penn to apply AAV technology to its developing gene-therapy program.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.